3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Spinal Cord Neoplasms
1
Pituitary Neoplasms
1
Parkinson Disease
1
Nervous System Diseases
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Hematologic Diseases
1
Epilepsy
1
Brain Neoplasms
1
Bone Marrow Diseases
1
Interventions
pirtobrutinib
3
Cyclophosphamide
3
Azacitidine
3
ibrutinib
2
fludarabine
2
Mycophenolic Acid
2
Lenalidomide
2
zanubrutinib
1
venetoclax
1
ruxolitinib
1
ponatinib
1
nilotinib
1
idelalisib
1
idecabtagene vicleucel
1
fludarabine phosphate
1
cedazuridine
1
cc-486
1
asciminib
1
acalabrutinib
1
Whole-Body Irradiation
1
Vancomycin
1
Tretinoin
1
Tacrolimus
1
Sirolimus
1
Semen Analysis
1
Rituximab
1
Quality of Life
1
Physical Examination
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Clinical Laboratory Techniques
×
90 days
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled